Charles River Laboratories International Inc
NYSE:CRL

Watchlist Manager
Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc
NYSE:CRL
Watchlist
Price: 195.77 USD 0.81% Market Closed
Market Cap: 10B USD
Have any thoughts about
Charles River Laboratories International Inc?
Write Note

Charles River Laboratories International Inc
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Charles River Laboratories International Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
Charles River Laboratories International Inc
NYSE:CRL
Total Assets
$8B
CAGR 3-Years
4%
CAGR 5-Years
12%
CAGR 10-Years
16%
Thermo Fisher Scientific Inc
NYSE:TMO
Total Assets
$100.4B
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
9%
Danaher Corp
NYSE:DHR
Total Assets
$80.6B
CAGR 3-Years
-1%
CAGR 5-Years
6%
CAGR 10-Years
9%
Mettler-Toledo International Inc
NYSE:MTD
Total Assets
$3.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Total Assets
$11B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Total Assets
$27.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
24%
No Stocks Found

Charles River Laboratories International Inc
Glance View

Market Cap
10B USD
Industry
Life Sciences Tools & Services

Charles River Laboratories International Inc. is a leading provider of essential research services and products that support the global clinical development of new drugs. Founded in 1947, the company has evolved from a small laboratory in Massachusetts to a formidable player within the biotech and pharmaceutical sectors. Its comprehensive suite of offerings includes preclinical and clinical laboratory services, along with a range of research models that help organizations like pharmaceutical companies and academic institutions navigate the complexities of drug development. By partnering with clients from early-stage discovery through to advanced trials, Charles River plays a pivotal role in bringing innovative therapies to market while maintaining a strong commitment to animal welfare and ethical research practices. As an investment opportunity, Charles River Laboratories stands out due to its solid financial performance, buoyed by a strategic focus on expanding its capabilities and services. The company has shown robust revenue growth over the years, driven by increasing demand for outsourced laboratory services, especially as the biotech landscape becomes more competitive. With a dedicated management team and a continual investment in technology and infrastructure, Charles River is well-positioned to capitalize on the rising need for more efficient drug development processes. Investors can take confidence from the company's strong market presence, consistent execution, and strategic acquisitions that enhance its service offerings, making it a compelling choice for those looking to invest in the healthcare space.

CRL Intrinsic Value
227.11 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Charles River Laboratories International Inc's Total Assets?
Total Assets
8B USD

Based on the financial report for Sep 28, 2024, Charles River Laboratories International Inc's Total Assets amounts to 8B USD.

What is Charles River Laboratories International Inc's Total Assets growth rate?
Total Assets CAGR 10Y
16%

Over the last year, the Total Assets growth was 5%. The average annual Total Assets growth rates for Charles River Laboratories International Inc have been 4% over the past three years , 12% over the past five years , and 16% over the past ten years .

Back to Top